Description
Book SynopsisThe understanding of drug-induced movement disorders is extremely difficult, and many physicians and clinicians find this a difficult and complex area to treat. The unique way in which the plethora of different drugs react and manifest with the patient's exact condition is particularly hard to manage and diagnose.
Trade Review"This well written comprehensive book provides the reader with good clinical descriptions of the major movement disorders and with extensively referenced data on studies and trials regarding both drugs incriminated in abnormal movements and those useful in their management."
"In conclusion, this comprehensive review of drug-induced movement disorders will be extremely useful to every clinician, particularly those interested in the fields of neurology and psychiatry."
Christian Wider, European Neurology, December 5th 2005
Table of ContentsSection 1: General Considerations.
Chapter 1: Movement Disorders: Approach, Definitions and differential Diagnosis.
Martin Cloutier, Anthony E. Lang.
Chapter 2: Rating Scales for Movement Disorders.
Wonodi I, Hong EH, Avila MT, Gunvant Thaker.
Chapter 3: Spontaneous movement disorders in psychiatric patients.
Irene Richard, Christopher O’Brien, Roger Kurlan.
Section 2: Antipsychotics.
Chapter 4: Pharmacology of typical and atypical agents.
Gary Remington, Shitij Kapur.
Chapter 5: Acute Drug-induced Dystonia.
Michael F. Mazurek, Patricia I. Rosebush.
Chapter 6: Drug-Induced Parkinsonism.
Joseph H. Friedman, Martha E. Trieschmann, Hubert H. Fernandez.
Chapter 7: Acute Akathisia.
Author: Lenard A. Adler, John Rotrosen, Burt Angrist.
Chapter 8: Neuroleptic Malignant Syndrome.
Stewart A. Factor.
Chapter 9: Classical Tardive Dyskinesia.
Thomas M. Hyde, MD, Jose A. Apud, Whitney C. Fisher, Michael F. Egan.
Chapter 10: Tardive dyskinesia Variants.
Skidmore F, Weiner W, Burke R.
Chapter 11: Movement Disorders caused by atypical antipsychotics.
Karen E. Anderson.
Chapter 12: Commentary: Is Tardive dyskinesia disappearing?James Lohr, MD.
.
.
Section 3: Dopaminomimetic Drugs.
Chapter 13: Dyskinesia induced by levodopa and dopamine agonists in Parkinson’s disease.
John G. Nutt, Matthew Brodsky.
Chapter 14: Stimulant Drugs.
Anthony E. Munson, Juan Sanchez-Ramos, William J Weiner.
Section 5: Other Drugs.
Chapter 15: Antidepressants.
Marie L. Moro-de-Casillas, David E. Riley.
Chapter 16: Anticonvulsants.
John C. Morgan, Madeline Harrison.
Chapter 17: Miscellaneous Drugs.
Daniel Tarsy
